• SENSEX
    NIFTY 50
Market

Thursday's top brokerage calls: Bajaj Auto, Dr Reddy's and more

Updated : 2020-05-21 08:39:58

Among brokerages, CLSA is bullish on Bajaj Auto post March quarter results and has raised its target price for the stock, while Jefferies maintained an 'underperform' call on Dr Reddy's. Here are the top brokerage calls for today:

 CLSA on Bajaj Auto:  The brokerage maintained a 'buy' call on the stock with target raised to Rs 3,000 per share from Rs 2,800 earlier. It added that Q4 results were significantly better than expectations.
CLSA on Bajaj Auto: The brokerage maintained a 'buy' call on the stock with target raised to Rs 3,000 per share from Rs 2,800 earlier. It added that Q4 results were significantly better than expectations.
 Nomura on Bajaj Auto:  The brokerage maintains a 'buy' call on the stock with a target at Rs 3,030 per share. It expects volume recovery for Bajaj Auto in H2.
Nomura on Bajaj Auto: The brokerage maintains a 'buy' call on the stock with a target at Rs 3,030 per share. It expects volume recovery for Bajaj Auto in H2.
 CLSA on Jubilant FoodWorks:  The brokerage maintained a 'buy' on the stock with target raised to Rs 1,850 from Rs 1,800 earlier. It believes the company's credible brand positioning with a trend toward food delivery should aid its market share.
CLSA on Jubilant FoodWorks: The brokerage maintained a 'buy' on the stock with target raised to Rs 1,850 from Rs 1,800 earlier. It believes the company's credible brand positioning with a trend toward food delivery should aid its market share.
 Jefferies on Dr Reddy's:  The brokerage maintained 'underperform' rating on the stock but raised target price to Rs 3,000 per share from Rs 2,500 earlier. FY21 will see increased R&D and capex for Dr Reddy’s, limiting margin improvement, Jefferies says.
Jefferies on Dr Reddy's: The brokerage maintained 'underperform' rating on the stock but raised target price to Rs 3,000 per share from Rs 2,500 earlier. FY21 will see increased R&D and capex for Dr Reddy’s, limiting margin improvement, Jefferies says.
 CLSA on Dr Reddy's:  The brokerage has an 'outperform' rating on the stock with target raised to Rs 4,450 from Rs 4,250 earlier.
CLSA on Dr Reddy's: The brokerage has an 'outperform' rating on the stock with target raised to Rs 4,450 from Rs 4,250 earlier.
 CLSA on UltraTech Cement : The brokerage maintained 'outperform' call on the stock with a target at Rs 3,925 per share. The company’s focus on cash conservation and debt reduction was a highlight in UltraTech’s Q4 results, CLSA said.
CLSA on UltraTech Cement: The brokerage maintained 'outperform' call on the stock with a target at Rs 3,925 per share. The company’s focus on cash conservation and debt reduction was a highlight in UltraTech’s Q4 results, CLSA said.
 Morgan Stanley on Jubilant FoodWorks:  The brokerage maintains 'overweight' call on the stock with a target at Rs 1,900 per share. Preparedness for new normal and cost control should drive speedy recovery for Jubilant Food going ahead, it says.
Morgan Stanley on Jubilant FoodWorks: The brokerage maintains 'overweight' call on the stock with a target at Rs 1,900 per share. Preparedness for new normal and cost control should drive speedy recovery for Jubilant Food going ahead, it says.
 Credit Suisse on Jubilant Food:  The brokerage maintains 'outperform' call on the stock with a target at Rs 1,625 per share. It cut the stock's FY21-22 earnings by 2-8 percent after Q4 earnings.
Credit Suisse on Jubilant Food: The brokerage maintains 'outperform' call on the stock with a target at Rs 1,625 per share. It cut the stock's FY21-22 earnings by 2-8 percent after Q4 earnings.
 Credit Suisse on UltraTech:  The brokerage maintains 'outperform' rating on the stock with target raised to Rs 4,500 per share from Rs 3,900 earlier. Overall EBITDA for the quarter-ended March largely met estimates given lower costs, it said.
Credit Suisse on UltraTech: The brokerage maintains 'outperform' rating on the stock with target raised to Rs 4,500 per share from Rs 3,900 earlier. Overall EBITDA for the quarter-ended March largely met estimates given lower costs, it said.
Live TV
Advertisement